Vor Biopharma Inc.
12/10/2023 | Press release | Distributed by Public on 12/10/2023 12:03
ASH – ORAL PRESENTATION – 483
December 10, 2023
ASH - ORAL PRESENTATION - 483
Trem-cel
Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)